**Executive takeaway:** Infleqtion (formerly ColdQuanta) is coming public via Churchill Capital Corp X (CCCX) at a **$1.8B pre-money equity value**—and based on its own disclosed financials, that implies a **much lower EV/Revenue profile than the “quantum cohort” multiples cited in the deal materials**, creating potential valuation “catch-up” *if* growth proves durable. ["pre-money equity value for Infleqtion of $1,800,000,000"](0001193125-26-021087|0) ["Quantum Technology Companies… LTM EV/Revenue"](0001193125-26-021087|0) At the same time, the filing shows several **diligence flags** that can explain a discount: (i) **very high government concentration**, (ii) a **large 2024 revenue step-up driven by specific awards (esp. UK)** with explicit disclosure that material UK contracts expired in 2025, (iii) **material weaknesses in ICFR**, and (iv) **non-trivial impairment charges** tied to acquisitions (Morton). ["36%, 32%, and 12% of total revenue"](0001193125-26-021087|0) ["contracts with the UK government that have now expired"](0001193125-26-021087|0) ["material weaknesses"](0001193125-26-021087|0) ["Impairment of acquired assets"](0001193125-26-021087|0) --- ## 1) What the “quantum company” actually is (per filings, not hype) The CCCX 425 you selected is a reprint of a Benzinga article describing the proposed deal between CCCX and ColdQuanta/Infleqtion, including the framing that Infleqtion focuses on **neutral-atom quantum computing and quantum sensing** and mentions a broad product portfolio. ["proposed business combination between Churchill Capital Corp X and ColdQuanta, Inc. (“Infleqtion”)"](0001193125-26-041848|0) ["neutral-atom technology"](0001193125-26-041848|0) The definitive disclosure backbone is the **CCCX/ColdQuanta 424B3 proxy statement/prospectus** (817 pages), which includes Infleqtion’s audited 2024/2023 financials and Sep 30, 2025 interim financials plus detailed risk factors. ["PROXY STATEMENT…"](0001193125-26-021087|0) --- ## 2) Financial reality check: Infleqtion’s disclosed scale, mix, and trajectory ### Revenue and profitability (Infleqtion standalone) Infleqtion reported **$28.836M revenue in 2024 vs $10.950M in 2023 (+163%)**, with **gross profit $9.064M** in 2024 and **operating loss $(53.008)M** in 2024. ["Total revenue 28,836"](0001193125-26-021087|0) ["Total revenue… 10,950"](0001193125-26-021087|0) ["Loss from operations (53,008)"](0001193125-26-021087|0) For the **nine months ended Sep 30, 2025**, revenue was **$21.674M** with **net loss $(21.035)M** (showing continuing losses, but less severe than the 9M24 period shown). ["Total revenue 21,674"](0001193125-26-021087|0) ["Net loss… (21,035)"](0001193125-26-021087|0) ### Revenue concentration and “quality” of the growth Infleqtion explicitly discloses significant concentration: in 2024, **36% (UK government), 32% (U.S. government), 12% (Japanese government)** of total revenue. ["36%, 32%, and 12% of total revenue"](0001193125-26-021087|0) Two important nuance points that are easy to miss: * The filing states that **~36% of 2024 revenue was related to UK government contracts that have now expired** (during 2025), and while management expects offsets from U.S./Australia growth, that is a key “growth-quality” question. ["36% of our revenue… UK government contracts… have now expired"](0001193125-26-021087|0) ["revenue from U.S. and Australian government contracts increased during 2025"](0001193125-26-021087|0) * The company also shows **very large accounts receivable concentration** at year-end: at Dec 31, 2024, **two customers represented 57% and 25% of A/R**. ["two customers represented 57% and 25%"](0001193125-26-021087|0) ### Backlog / remaining performance obligations (near-term visibility) Infleqtion disclosed remaining performance obligations of **$12.9M for 2025** and **$1.7M for 2026** (non-cancelable). ["expects to recognize revenue of $12.9 million and $1.7 million"](0001193125-26-021087|0) --- ## 3) Peer anomaly work: where Infleqtion looks *different* vs public “quantum” comps ### (A) Valuation multiple gap: Infleqtion screens cheap vs the cohort (from the deal’s own comp table) The proxy includes a table of **LTM EV/Revenue** multiples for “Selected Quantum Publicly Traded Companies” (as used by Ocean Tomo), e.g. **IonQ 221.2x**, **D‑Wave 202.2x**, **Rigetti 573.1x**, **Quantum Computing Inc. 7,940.8x**. ["IonQ, Inc.… 221.2 x"](0001193125-26-021087|0) ["D-Wave Quantum Inc.… 202.2 x"](0001193125-26-021087|0) ["Rigetti Computing, Inc.… 573.1 x"](0001193125-26-021087|0) ["Quantum Computing Inc.… 7,940.8 x"](0001193125-26-021087|0) Infleqtion’s purchase price is repeatedly treated as **$1.8B**. ["assumed that the Purchase Price… had a value equal to $1.8 billion"](0001193125-26-021087|0) Infleqtion’s 2024 revenue is **$28.836M**. ["Total revenue 28,836"](0001193125-26-021087|0) So at face value, Infleqtion’s implied **Equity Value / 2024 revenue ≈ 62.4x (computed)** (= $1,800M / $28.836M), which is **far below** the cohort multiples the same document displays. ["$1.8 billion"](0001193125-26-021087|0) ["Total revenue 28,836"](0001193125-26-021087|0) **Potential alpha interpretation:** if the market continues to price “quantum” primarily on long-dated optionality (as Ocean Tomo itself notes), a “cheaper entry multiple” for a name with >$20M revenue scale could rerate—*but only if growth is not just a one-off government award cycle.* ["quantum industry are not being priced on the next three years of revenue"](0001193125-26-021087|0) ### (B) Revenue scale vs peers (filing-to-filing comparison) Using each peer’s latest 10‑K (FY2024 where available): * **IonQ FY2024 total revenue: $43.073M**. ["Total revenue… 43,073"](0000950170-25-027722|0) * **Rigetti FY2024 total revenue: $10.790M**. ["Total revenue… 10,790"](0001558370-25-002499|0) * **D‑Wave FY2024 total revenue: $8.827M**. ["Total revenue… 8,827"](0001907982-25-000060|0) * **Quantum Computing Inc (QUBT) FY2024 total revenue: $0.373M**. ["Total revenue… 373"](0001213900-25-025561|0) * **Infleqtion FY2024 total revenue: $28.836M**. ["Total revenue 28,836"](0001193125-26-021087|0) So Infleqtion is **smaller than IonQ but materially larger than D‑Wave/Rigetti/QUBT on a revenue basis**, which can matter if the market is paying for “proof of commercial life,” not just qubit roadmaps. ["Total revenue 28,836"](0001193125-26-021087|0) ["Total revenue… 43,073"](0000950170-25-027722|0) ["Total revenue… 8,827"](0001907982-25-000060|0) ["Total revenue… 10,790"](0001558370-25-002499|0) ["Total revenue… 373"](0001213900-25-025561|0) ### (C) Government dependence: not unique, but Infleqtion’s *composition* is a bit different Rigetti discloses **sales to government entities were 89.4% (2024)**. ["sales to government entities comprised 89.4%"](0001558370-25-002499|0) Infleqtion discloses government customers comprised **80% of total revenue in 2024**. ["Revenue from government customers comprised 80%"](0001193125-26-021087|0) So “high government mix” is not an Infleqtion-only phenomenon; the more interesting anomaly is **Infleqtion’s explicit exposure to expiring UK government contracts that were a huge chunk of 2024 revenue**. ["36% of our revenue… UK government contracts… have now expired"](0001193125-26-021087|0) --- ## 4) “Interesting stuff” / diligence flags that could explain mispricing (and could become catalysts) ### (1) Internal controls: material weaknesses (real risk for de-SPAC transitions) Infleqtion discloses it **identified material weaknesses in internal control over financial reporting**, including (among others) IT segregation of duties and controls around UK subsidiary accounting and equity transactions. ["identified material weaknesses"](0001193125-26-021087|0) ["UK subsidiary or our system of record over equity transactions"](0001193125-26-021087|0) This matters because early post-close restatements / late filings often hit de-SPAC stocks disproportionately (liquidity + credibility). ### (2) Acquisition-related impairments: possible “integration/overpayment” smell test Infleqtion shows **impairment of acquired assets $13.539M** in 2024 (line item). ["Impairment of acquired assets… 13,539"](0001193125-26-021087|0) It also describes a **Morton acquisition** (Jan 25, 2024) with **purchase consideration $3.9M**, including contingent consideration. ["acquired 100%… Morton"](0001193125-26-021087|0) ["purchase consideration of $3.9 million"](0001193125-26-021087|0) The presence of both an acquisition and meaningful impairment charges in the same general timeframe is something I’d pressure-test (what was impaired—technology, goodwill, customer relationships; and does it repeat). ### (3) SPAC cash reality vs headline “proceeds” The PIPE is **$126.5476M at $10.00/share**, but the doc also highlights how net cash outcomes vary massively with redemptions (e.g., net cash per share examples). ["$126,547,600… at a purchase price of $10.00 per share"](0001193125-26-021087|0) ["Net Cash per share… $2.36… $0.51"](0001193125-26-021087|0) **Alpha setup:** if redemptions are high, the post-close company can end up undercapitalized relative to the narrative, which can create (a) downside risk, but also (b) *forced-financing* events or strategic partner capital that reprice the equity. ### (4) The “step-up” from last private round to deal price Ocean Tomo’s discussion references Infleqtion’s **Series C valuation of $707M as of 12/27/2024** and analyzes multiple expansion to support higher value. ["valuation… December 27, 2024 was $707 million"](0001193125-26-021087|0) That’s a *big* valuation jump to a $1.8B pre-money transaction value within <1 year; the core question is whether the revenue growth and bookings/backlog support it, or whether the public market is being asked to underwrite a sentiment-driven “multiple expansion.” --- ## 5) Concrete “alpha angles” to investigate next (all filing-grounded) If you want to keep digging, these are the highest signal next threads (and why they could create alpha): 1) **UK revenue replacement proof-points:** Management says UK contracts that were ~36% of 2024 revenue expired, but expects offsets via U.S./Australia increases. The alpha is whether disclosures later show *actual conversion into follow-on awards vs optimism*. ["36% of our revenue… expired"](0001193125-26-021087|0) ["expect will offset"](0001193125-26-021087|0) 2) **Customer concentration vs durability:** 2024 revenue is extremely concentrated by government counterparties, and A/R concentration is high. Any new disclosure that diversifies customers (or loses one) will move the stock. ["36%, 32%, and 12%"](0001193125-26-021087|0) ["57% and 25% of total accounts receivable"](0001193125-26-021087|0) 3) **Control remediation timeline:** remediation “may extend into 2026.” If this drags, it can become a persistent overhang; if it resolves cleanly, it can remove a discount. ["may extend into 2026"](0001193125-26-021087|0) 4) **Valuation rerate vs peers:** The proxy itself gives you the peer multiple reference frame; Infleqtion can rerate upward if it hits a credible growth path. ["LTM EV/Revenue"](0001193125-26-021087|0) --- ### If you want, I can go one level deeper on *specific anomalies* Tell me which vector you care about most, and I’ll pull the exact sections/chunks: * **Revenue recognition / contract accounting** (where “over-time” government contract accounting can create timing noise). ["recognized over time using cost input methods"](0001193125-26-021087|0) * **Ocean Tomo scenario assumptions** (e.g., “R&D costs 400% of revenue” scenario sensitivity). ["research and development costs in 2025 and 2026 are 400% of revenue"](0001193125-26-021087|0) * **SPAC mechanics** (share count, sponsor promotes, dilution tables, redemption breakpoints). ["Valuation… to achieve CCX IPO Price Per Share"](0001193125-26-021087|0)

**Executive takeaway:** Infleqtion (formerly ColdQuanta) is coming public via Churchill Capital Corp X (CCCX) at a **$1.8B pre-money equity value**—and based on its own disclosed financials, that implies a **much lower EV/Revenue profile than the “quantum cohort” multiples cited in the deal materials**, creating potential valuation “catch-up” *if* growth proves durable. ["pre-money equity value for Infleqtion of $1,800,000,000"](0001193125-26-021087|0) ["Quantum Technology Companies… LTM EV/Revenue"](0001193125-26-021087|0) At the same time, the filing shows several **diligence flags** that can explain a discount: (i) **very high government concentration**, (ii) a **large 2024 revenue step-up driven by specific awards (esp. UK)** with explicit disclosure that material UK contracts expired in 2025, (iii) **material weaknesses in ICFR**, and (iv) **non-trivial impairment charges** tied to acquisitions (Morton). ["36%, 32%, and 12% of total revenue"](0001193125-26-021087|0) ["contracts with the UK government that have now expired"](0001193125-26-021087|0) ["material weaknesses"](0001193125-26-021087|0) ["Impairment of acquired assets"](0001193125-26-021087|0) --- ## 1) What the “quantum company” actually is (per filings, not hype) The CCCX 425 you selected is a reprint of a Benzinga article describing the proposed deal between CCCX and ColdQuanta/Infleqtion, including the framing that Infleqtion focuses on **neutral-atom quantum computing and quantum sensing** and mentions a broad product portfolio. ["proposed business combination between Churchill Capital Corp X and ColdQuanta, Inc. (“Infleqtion”)"](0001193125-26-041848|0) ["neutral-atom technology"](0001193125-26-041848|0) The definitive disclosure backbone is the **CCCX/ColdQuanta 424B3 proxy statement/prospectus** (817 pages), which includes Infleqtion’s audited 2024/2023 financials and Sep 30, 2025 interim financials plus detailed risk factors. ["PROXY STATEMENT…"](0001193125-26-021087|0) --- ## 2) Financial reality check: Infleqtion’s disclosed scale, mix, and trajectory ### Revenue and profitability (Infleqtion standalone) Infleqtion reported **$28.836M revenue in 2024 vs $10.950M in 2023 (+163%)**, with **gross profit $9.064M** in 2024 and **operating loss $(53.008)M** in 2024. ["Total revenue 28,836"](0001193125-26-021087|0) ["Total revenue… 10,950"](0001193125-26-021087|0) ["Loss from operations (53,008)"](0001193125-26-021087|0) For the **nine months ended Sep 30, 2025**, revenue was **$21.674M** with **net loss $(21.035)M** (showing continuing losses, but less severe than the 9M24 period shown). ["Total revenue 21,674"](0001193125-26-021087|0) ["Net loss… (21,035)"](0001193125-26-021087|0) ### Revenue concentration and “quality” of the growth Infleqtion explicitly discloses significant concentration: in 2024, **36% (UK government), 32% (U.S. government), 12% (Japanese government)** of total revenue. ["36%, 32%, and 12% of total revenue"](0001193125-26-021087|0) Two important nuance points that are easy to miss: * The filing states that **~36% of 2024 revenue was related to UK government contracts that have now expired** (during 2025), and while management expects offsets from U.S./Australia growth, that is a key “growth-quality” question. ["36% of our revenue… UK government contracts… have now expired"](0001193125-26-021087|0) ["revenue from U.S. and Australian government contracts increased during 2025"](0001193125-26-021087|0) * The company also shows **very large accounts receivable concentration** at year-end: at Dec 31, 2024, **two customers represented 57% and 25% of A/R**. ["two customers represented 57% and 25%"](0001193125-26-021087|0) ### Backlog / remaining performance obligations (near-term visibility) Infleqtion disclosed remaining performance obligations of **$12.9M for 2025** and **$1.7M for 2026** (non-cancelable). ["expects to recognize revenue of $12.9 million and $1.7 million"](0001193125-26-021087|0) --- ## 3) Peer anomaly work: where Infleqtion looks *different* vs public “quantum” comps ### (A) Valuation multiple gap: Infleqtion screens cheap vs the cohort (from the deal’s own comp table) The proxy includes a table of **LTM EV/Revenue** multiples for “Selected Quantum Publicly Traded Companies” (as used by Ocean Tomo), e.g. **IonQ 221.2x**, **D‑Wave 202.2x**, **Rigetti 573.1x**, **Quantum Computing Inc. 7,940.8x**. ["IonQ, Inc.… 221.2 x"](0001193125-26-021087|0) ["D-Wave Quantum Inc.… 202.2 x"](0001193125-26-021087|0) ["Rigetti Computing, Inc.… 573.1 x"](0001193125-26-021087|0) ["Quantum Computing Inc.… 7,940.8 x"](0001193125-26-021087|0) Infleqtion’s purchase price is repeatedly treated as **$1.8B**. ["assumed that the Purchase Price… had a value equal to $1.8 billion"](0001193125-26-021087|0) Infleqtion’s 2024 revenue is **$28.836M**. ["Total revenue 28,836"](0001193125-26-021087|0) So at face value, Infleqtion’s implied **Equity Value / 2024 revenue ≈ 62.4x (computed)** (= $1,800M / $28.836M), which is **far below** the cohort multiples the same document displays. ["$1.8 billion"](0001193125-26-021087|0) ["Total revenue 28,836"](0001193125-26-021087|0) **Potential alpha interpretation:** if the market continues to price “quantum” primarily on long-dated optionality (as Ocean Tomo itself notes), a “cheaper entry multiple” for a name with >$20M revenue scale could rerate—*but only if growth is not just a one-off government award cycle.* ["quantum industry are not being priced on the next three years of revenue"](0001193125-26-021087|0) ### (B) Revenue scale vs peers (filing-to-filing comparison) Using each peer’s latest 10‑K (FY2024 where available): * **IonQ FY2024 total revenue: $43.073M**. ["Total revenue… 43,073"](0000950170-25-027722|0) * **Rigetti FY2024 total revenue: $10.790M**. ["Total revenue… 10,790"](0001558370-25-002499|0) * **D‑Wave FY2024 total revenue: $8.827M**. ["Total revenue… 8,827"](0001907982-25-000060|0) * **Quantum Computing Inc (QUBT) FY2024 total revenue: $0.373M**. ["Total revenue… 373"](0001213900-25-025561|0) * **Infleqtion FY2024 total revenue: $28.836M**. ["Total revenue 28,836"](0001193125-26-021087|0) So Infleqtion is **smaller than IonQ but materially larger than D‑Wave/Rigetti/QUBT on a revenue basis**, which can matter if the market is paying for “proof of commercial life,” not just qubit roadmaps. ["Total revenue 28,836"](0001193125-26-021087|0) ["Total revenue… 43,073"](0000950170-25-027722|0) ["Total revenue… 8,827"](0001907982-25-000060|0) ["Total revenue… 10,790"](0001558370-25-002499|0) ["Total revenue… 373"](0001213900-25-025561|0) ### (C) Government dependence: not unique, but Infleqtion’s *composition* is a bit different Rigetti discloses **sales to government entities were 89.4% (2024)**. ["sales to government entities comprised 89.4%"](0001558370-25-002499|0) Infleqtion discloses government customers comprised **80% of total revenue in 2024**. ["Revenue from government customers comprised 80%"](0001193125-26-021087|0) So “high government mix” is not an Infleqtion-only phenomenon; the more interesting anomaly is **Infleqtion’s explicit exposure to expiring UK government contracts that were a huge chunk of 2024 revenue**. ["36% of our revenue… UK government contracts… have now expired"](0001193125-26-021087|0) --- ## 4) “Interesting stuff” / diligence flags that could explain mispricing (and could become catalysts) ### (1) Internal controls: material weaknesses (real risk for de-SPAC transitions) Infleqtion discloses it **identified material weaknesses in internal control over financial reporting**, including (among others) IT segregation of duties and controls around UK subsidiary accounting and equity transactions. ["identified material weaknesses"](0001193125-26-021087|0) ["UK subsidiary or our system of record over equity transactions"](0001193125-26-021087|0) This matters because early post-close restatements / late filings often hit de-SPAC stocks disproportionately (liquidity + credibility). ### (2) Acquisition-related impairments: possible “integration/overpayment” smell test Infleqtion shows **impairment of acquired assets $13.539M** in 2024 (line item). ["Impairment of acquired assets… 13,539"](0001193125-26-021087|0) It also describes a **Morton acquisition** (Jan 25, 2024) with **purchase consideration $3.9M**, including contingent consideration. ["acquired 100%… Morton"](0001193125-26-021087|0) ["purchase consideration of $3.9 million"](0001193125-26-021087|0) The presence of both an acquisition and meaningful impairment charges in the same general timeframe is something I’d pressure-test (what was impaired—technology, goodwill, customer relationships; and does it repeat). ### (3) SPAC cash reality vs headline “proceeds” The PIPE is **$126.5476M at $10.00/share**, but the doc also highlights how net cash outcomes vary massively with redemptions (e.g., net cash per share examples). ["$126,547,600… at a purchase price of $10.00 per share"](0001193125-26-021087|0) ["Net Cash per share… $2.36… $0.51"](0001193125-26-021087|0) **Alpha setup:** if redemptions are high, the post-close company can end up undercapitalized relative to the narrative, which can create (a) downside risk, but also (b) *forced-financing* events or strategic partner capital that reprice the equity. ### (4) The “step-up” from last private round to deal price Ocean Tomo’s discussion references Infleqtion’s **Series C valuation of $707M as of 12/27/2024** and analyzes multiple expansion to support higher value. ["valuation… December 27, 2024 was $707 million"](0001193125-26-021087|0) That’s a *big* valuation jump to a $1.8B pre-money transaction value within <1 year; the core question is whether the revenue growth and bookings/backlog support it, or whether the public market is being asked to underwrite a sentiment-driven “multiple expansion.” --- ## 5) Concrete “alpha angles” to investigate next (all filing-grounded) If you want to keep digging, these are the highest signal next threads (and why they could create alpha): 1) **UK revenue replacement proof-points:** Management says UK contracts that were ~36% of 2024 revenue expired, but expects offsets via U.S./Australia increases. The alpha is whether disclosures later show *actual conversion into follow-on awards vs optimism*. ["36% of our revenue… expired"](0001193125-26-021087|0) ["expect will offset"](0001193125-26-021087|0) 2) **Customer concentration vs durability:** 2024 revenue is extremely concentrated by government counterparties, and A/R concentration is high. Any new disclosure that diversifies customers (or loses one) will move the stock. ["36%, 32%, and 12%"](0001193125-26-021087|0) ["57% and 25% of total accounts receivable"](0001193125-26-021087|0) 3) **Control remediation timeline:** remediation “may extend into 2026.” If this drags, it can become a persistent overhang; if it resolves cleanly, it can remove a discount. ["may extend into 2026"](0001193125-26-021087|0) 4) **Valuation rerate vs peers:** The proxy itself gives you the peer multiple reference frame; Infleqtion can rerate upward if it hits a credible growth path. ["LTM EV/Revenue"](0001193125-26-021087|0) --- ### If you want, I can go one level deeper on *specific anomalies* Tell me which vector you care about most, and I’ll pull the exact sections/chunks: * **Revenue recognition / contract accounting** (where “over-time” government contract accounting can create timing noise). ["recognized over time using cost input methods"](0001193125-26-021087|0) * **Ocean Tomo scenario assumptions** (e.g., “R&D costs 400% of revenue” scenario sensitivity). ["research and development costs in 2025 and 2026 are 400% of revenue"](0001193125-26-021087|0) * **SPAC mechanics** (share count, sponsor promotes, dilution tables, redemption breakpoints). ["Valuation… to achieve CCX IPO Price Per Share"](0001193125-26-021087|0)